Recent Press Releases

Agile Therapeutics, Inc. Appoints John Hubbard, Ph.D., FCP To Its Board Of Directors

PRINCETON, N.J., Nov. 18, 2014 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (Nasdaq:AGRX) today announced that John Hubbard, Ph.D., FCP has been appointed to the Company's Board of Directors,...

BioTelemetry, Inc. Announces That Eric Prystowsky M.D. Will Transition From The Board Of Directors Into A Medical Advisory Role

MALVERN, Pa., Nov. 19, 2014 (GLOBE NEWSWIRE) -- BioTelemetry, Inc. (Nasdaq:BEAT), the leading wireless medical technology company focused on the delivery of health information to improve quality of...

Piedmont Pharmaceuticals Prepares For Veterinary Companion Animal Product Launches

GREENSBORO, NC--(Marketwired - November 19, 2014) - Piedmont Pharmaceuticals, LLC, an innovative pharmaceutical company focused on veterinary market pharmaceuticals, today announced its hiring of Mr....

Dr. James M. Wilson Joins REGENXBIO As Chief Scientific Advisor

WASHINGTON, Nov. 18, 2014 (GLOBE NEWSWIRE) -- REGENXBIO Inc. today announced that James M. Wilson, M.D., Ph.D. has been named its Chief Scientific Advisor, effective immediately. Dr. Wilson is also...

Retrophin (RTRX) Names Margaret Valeur-Jensen, Ph.D. As General Counsel

NEW YORK--(BUSINESS WIRE)--Retrophin, Inc. (NASDAQ:RTRX) today announced the appointment of Margaret Valeur-Jensen, Ph.D. to the newly created position of General Counsel, effective immediately. She...

Vermillion Outlines Expanded Strategic Mission; Forms New Strategic & Medical Advisory Board

AUSTIN, Texas, Nov. 18, 2014 /PRNewswire/ -- Vermillion, Inc. (NASDAQ: VRML), a bio-analytical solutions company focused on gynecologic disease, recently outlined its expanded strategy for driving...

LEO Pharma Appoints Barbara Osborne As President & CEO Of LEO U.S. Region

PARSIPPANY, New Jersey, November 19, 2014 /PRNewswire/ -- LEO Pharma Inc. announced it has named Barbara J. Osborne as President and Chief Executive Officer (CEO) of LEO Pharma U.S. Region. She will...

Intellipharmaceutics Announces Appointment Of New Chief Financial Officer

TORONTO, Nov. 18, 2014 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel...

Mela Sciences (MELA) Names Michael R. Stewart Its Next President And CEO

IRVINGTON, N.Y., Nov. 19, 2014 (GLOBE NEWSWIRE) -- MELA Sciences, Inc. (Nasdaq:MELA), developer of the MelaFind® system, a non-invasive software-driven image analysis device approved for use in...

FDA approves extended-release, single-entity hydrocodone product with abuse-deterrent properties

The U.S. Food and Drug Administration today approved Hysingla ER (hydrocodone bitartrate), an extended-release (ER) opioid analgesic to treat pain severe enough to require daily, around-the-clock,...

Ikaria and Lee's Pharmaceutical Announce Strategic Partnership for the Registration and Commercialization of Ikaria's INOMAX® Total Care Package in the People's Republic of China, Hong Kong, Macau and Taiwan

PR Newswire HAMPTON, N.J. and HONG KONG, Nov. 19, 2014 HAMPTON, N.J. and HONG KONG, Nov. 19, 2014 /PRNewswire/ -- Ikaria, Inc. (through its INO Therapeutics subsidiary) and Lee's Pharmaceutical...

Ironwood Earns $15 Million Milestone from Astellas upon Initiation of Enrollment in Linaclotide Phase III IBS-C Clinical Trial in Japan

CAMBRIDGE, Mass.-- Ironwood Pharmaceuticals, Inc. (IRWD) announced today that it has earned a $15 million development milestone payment from Astellas Pharma Inc., its partner for linaclotide in...

N30 Pharmaceuticals Secures $30 Million in Oversubscribed Crossover Financing

BOULDER, Colo., Nov. 19, 2014 /PRNewswire/ -- N30 Pharmaceuticals, Inc. ("N30 Pharma"), a clinical-stage, biopharmaceutical company focused on the development of therapies for cystic...

Fred Hutch announces Dr. Gary Gilliland as new president and director

She was only 42 and she was married to a snowplow operator. The years fall away and the details come into sharp focus as Dr. Gary Gilliland recalls meeting the patient who would shape the...

Interim Data from Rociletinib (CO-1686) Phase 1/2 Study Shows Compelling and Durable Clinical Activity and Progression-free Survival (PFS) in Patients with EGFR-Mutant Non-small Cell Lung Cancer (NSCLC)

67% objective response rate (ORR) observed in evaluable heavily-pretreated T790M+ patients treated with 625mg or 500mg BID (clinical dose group) Median PFS of 10.4 months in clinical dose group; data...

ABPI comments on the Innovative Medicines and MedTech Review

ABPI Chief Executive, Stephen Whitehead, comments on the announcement by the Government of a new initiative to accelerate access for NHS patients to new medical innovations and a review of the...

BioIndustry Association welcomes government review to accelerate access to innovative medicines and deliver 21st century healthcare through the NHS

At a meeting of life science industry leaders, regulators and health officials at 10 Downing Street this morning, three years since the launch of the Strategy for UK Life Sciences, Life Sciences...

Major investment in life sciences

New investment into life sciences announced alongside a review into how we develop medicines and medical technology. Since the Prime Minister launched the industrial strategy in life sciences 3 years...

NW BIO ANNOUNCES FINANCINGS TOTALING $35 MILLION TO EXPAND AND ACCELERATE DCVAX®-L AND DCVAX®-DIRECT PROGRAMS

NW BIO ANNOUNCES FINANCINGS TOTALING $35 MILLION TO EXPAND AND ACCELERATE DCVAX®-L AND DCVAX®-DIRECT PROGRAMS Funding Includes $25 Million Equity Investment By Leading UK Investment Fund and...